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The Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in
death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of
<120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the
applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical
and economic implications of this intensive SBP treatment among those meeting SPRINT
eligibility.
Methods and findings
We used nationally representative baseline data from the China Health and Retirement
Longitudinal Study (CHARLS) (2011–2012) to estimate the prevalence and number of Chi-
nese adults aged 45 years and older who meet SPRINT criteria. A validated microsimula-
tion model was employed to project costs, clinical outcomes, and quality-adjusted life-
years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies
(SBP goal of <120 mm Hg [intensive treatment] and SBP goal of <140 mm Hg [standard
treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to
124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0)
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million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI
22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihy-
pertensive medication. We estimated that over 5 years, compared to standard treatment,
intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) mil-
lion cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84
(95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI −0.28,
0.42) million myocardial infarction cases and 0.36 (95% CI −0.10, 0.82) million stroke
cases were not statistically significant. Furthermore, over a lifetime, moving from standard
to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38
[95% CI 0.13 to 0.71]), at a cost of Int$10,997 per QALY gained. Of all 1-way sensitivity
analyses, high antihypertensive drug cost and lower treatment efficacy for CVD death
resulted in the 2 most unfavorable results (Int$25,291 and Int$18,995 per QALY were
gained, respectively). Simulation results indicated that intensive treatment could be cost-
effective (82.8% probability of being below the willingness-to-pay threshold of Int$16,782
[1× GDP per capita in China in 2017]), with a lower probability in people with SBP 130–139
mm Hg (72.9%) but a higher probability among females (91.2%). Main limitations include
lack of specific SPRINT eligibility information in the CHARLS survey, uncertainty about
the implications of different blood pressure measurement techniques, the use of several
sources of data with large reliance on findings from SPPRINT, limited information about
the serious adverse event rate, and lack of information and evidence for medication effec-
tiveness on renal disease.
Conclusions
Although adoption of the SPRINT treatment strategy would increase the number of Chi-
nese adults requiring SBP treatment intensification, this approach has the potential to pre-
vent CVD events, to produce gains in life-years, and to be cost-effective under common
thresholds.
Author summary
Why was this study done?
• The Systolic Blood Pressure Intervention Trial (SPRINT) has previously demonstrated
significant reductions in death and cardiovascular disease (CVD) risk with a systolic
blood pressure (SBP) goal of< 120 mm Hg (intensive treatment) compared with a SBP
goal of<140 mm Hg (standard treatment).
• A large proportion of Chinese adults are classified as hypertensive but few of them
achieve recommended blood pressure targets.
What did the researchers do and find?
• We used nationally representative data from the China Health and Retirement Longitu-
dinal Study (CHARLS) (2011–2012) to assess the applicability of SPRINT to the Chinese
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adult population, and a validated microsimulation model to predict the cost-effectiveness
of this intensive treatment among those meeting the SPRINT eligibility criteria for inten-
sive treatment.
• It is estimated that 116.2 million adults in China are eligible for the SPRINT intensive
treatment strategy.
• If adopted, intensive treatment has the potential to prevent 2.03 million CVD deaths,
with a potential gain of 3.84 million more life-years over 5 years, and would likely be
cost-effective over a lifetime.
What do these findings mean?
• A substantial number of Chinese adults meet SPRINT eligibility criteria for intensive
blood pressure treatment.
• This evidence suggests that intensive treatment among high-risk populations could be
cost-effective.
Introduction
Elevated blood pressure (BP) is the leading risk factor for cardiovascular diseases (CVDs) in
China [1]. In 2015 a systolic BP (SBP) of 140 mm Hg or higher was found to be associated
with over 1.7 million deaths and more than 32 million disability-adjusted life-years in China,
accounting for more than 22% of global health losses from hypertension over that year [2].
Despite safe and effective antihypertensive medications having been available for decades and
recommended for use under the current guideline [3,4], China still faces huge challenges with
its low hypertension control rate and increasing hypertension in both prevalence and absolute
numbers [5–7]. It is clear that better management is required to address this growing burden
of hypertension.
The landmark Systolic Blood Pressure Intervention Trial (SPRINT) found that participants
assigned to intensive treatment (SBP goal of<120 mm Hg) had an 25% reduction in major
cardiovascular events and deaths compared with standard treatment (SBP goal of<140 mm
Hg), and all-cause mortality was reduced by 27% [8]. This significant finding was supported
by 2 meta-analyses of randomized clinical trials [9,10] and had far-reaching implications for
hypertension guidelines across the world [11,12].
The generalizability of the SPRINT intensive SBP treatment strategy to the Chinese popula-
tion is unclear, and the costs incurred from intensive drug treatment and adverse events need
to be weighed against the gains from preventing cardiovascular morbidity and mortality. We
explored the potential benefits that could be achieved through implementing the intensive SBP
treatment goal strategy proposed in SPRINT among Chinese adults. Our study used a nation-
ally representative dataset from China and a microsimulation model, aiming to (1) estimate
the numbers of Chinese adults who meet the SPRINT eligibility criteria and describe their
characteristics, (2) predict medium- and long-term associated cardiovascular risk and mortal-
ity, and (3) evaluate the lifetime cost-effectiveness of intensive SBP treatment versus standard
treatment among adults meeting SPRINT eligibility criteria.
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Methods
This study is composed of 2 parts: population analysis and health economic modeling. It was
planned at the time of study conception on the basis of our previous work [13], although no
formal prospective analysis plan was recorded. A further analysis of splitting the total cost into
its components was added in response to a peer reviewer’s comments (see Table G in S1 Text).
This study is reported as per the Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) guideline (S1 CHEERS Checklist).
Design of population study
Data source and study population. We used the national baseline database of the China
Health and Retirement Longitudinal Study (CHARLS), which was conducted in 2011–2012
and included 17,708 people. The study design for CHARLS has been reported previously
[14,15]. CHARLS is a nationally representative survey of people aged 45 years and older in
China, and participants are followed up biennially. CHARLS data are available via the website
http://charls.pku.edu.cn/pages/data/2011-charls-wave1/en.html. Other relevant data are pre-
sented here and in S1 Text. Study participants are selected through multistage probability sam-
pling and can be weighted to obtain national estimates. Detailed data including demographic
characteristics, medical history, prescription drug use, clinical measurement, and laboratory
testing are collected by standard questionnaires. Definitions for variables used in our study
can be found in “Study variables and definition” in S1 Text. The ethics committee of Peking
University Health Science Center approved CHARLS, and all participants gave written
informed consent before participation.
Analytical approach. Potential eligibility for SPRINT was determined using a multistep
algorithm. The sample needed to meet the following criteria: age� 50 years; SBP 130–180 mm
Hg on 0 or 1 antihypertensive medication class, 130–170 mm Hg on up to 2 classes, 130–160
mm Hg on up to 3 classes, or 130–150 mm Hg on up to 4 classes; and the presence of 1 or
more high CVD risk conditions. Despite being part of the eligibility criteria, antihypertensive
medication classes are not reported in the CHARLS database, and so in the present study we
used the slightly less restrictive criterion SBP 130–180 mm Hg on any number of antihyperten-
sive medication classes. High CVD risk conditions were defined as 1 or more of the following:
history of coronary heart disease, estimated glomerular filtration rate (eGFR) of 20 to 59 ml/
min/1.73 m2, 10-year risk for CVD� 15% calculated using the Framingham risk score for gen-
eral clinical practice, and age� 75 years. Participants were not eligible if they had any of the
following exclusion criteria: diabetes, a history of stroke, heart failure (HF), or end-stage renal
disease. The demographic and clinical characteristics of Chinese adults meeting SPRINT eligi-
bility criteria are presented in Table A in S1 Text. The absolute numbers overall and for sub-
groups of Chinese adults meeting each sequential SPRINT eligibility criterion were estimated
using survey analyses with patient-level sampling weights for China.
Design of the health economic model
We developed a microsimulation model to project healthcare costs, clinical outcomes, and
quality-adjusted life-years (QALYs) among the SPRINT-eligible Chinese adults for antihyper-
tensive treatment (regardless of their BP treatment history) under 2 alternative SBP treatment
strategies: SBP goal of<120 mm Hg (intensive treatment) versus SBP goal of<140 mm Hg
(standard treatment). In order to maintain the correlations between the attributes of individu-
als (e.g., age, sex, SBP), we bootstrapped 10,000 real individuals meeting SPRINT eligibility cri-
teria from CHARLS using TreeAge Pro 2018 R1.1. This approach contrasts with simulating
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hypothetical individuals via the distribution of each independent variable (e.g., mean and stan-
dard deviation for age), as the authors have done previously [13].
Model structure. In line with our previous work [13], our model is structured around 9
distinct health states. At the end of every model cycle (i.e., 1 year), an individual will either
transit to another health state or remain in the same state, with the probabilities sampled from
defined distributions. Subsequent to a primary event (i.e., myocardial infarction [MI], HF, or
stroke), patients move to a chronic heath state in which they have a higher risk of experiencing
a further CVD event or death. Also, our model includes the disease pathway of experiencing
more than 1 event (e.g., the occurrence of stroke after MI) during the first year of primary
event. In SPRINT, it was reported that intensive SBP treatment could increase the risk of spe-
cific adverse events, such as hypotension, syncope, electrolyte abnormalities, and acute kidney
injury. However, due to the lack of local data from China, we did not specify the individual
serious adverse events (SAEs) as in SPRINT. Therefore, we included a category of combined
SAEs to capture the costs and harms incurred from intensive SBP treatment. Additionally, we
assumed the risk of a CVD event would be the same for those with and without SAEs in our
model. The overall disease path is described in S1 Fig, and the detailed disease states within
each path can be found in our previous publication [13].
Transition probabilities. We estimated the primary incidence of MI/stroke [16] and HF
[17] by their corresponding and validated risk equations using the individual characteristics of
the SPRINT-eligible people in CHARLS. Other probabilities—including those of chronic con-
ditions followed by a primary event, secondary events, and SAEs from antihypertensive medi-
cations—were derived from national sources and published literature. The values for the
transition probabilities and their distributions are summarized in Table C in S1 Text.
Cost and utility weights. Costs were considered from a payer’s perspective. All costs are
reported in 2017 international dollars according to the exchange rate published by the World
Bank, based on purchasing power parity (PPP) methods (Int$1.00 = 3.54 yuan) [18]. All future
costs and QALYs were discounted at 3% annually. Total costs included antihypertension treat-
ment costs, cost of complications, and SAE costs. Specifically, for costs of BP medications, we
used a nationwide cross-sectional survey on the costs and frequencies of each standard antihy-
pertensive drug class within the combinations of medications [4] recommended by 2018 Chi-
nese guidelines for the management of hypertension [19]. For the costs of a CVD event, we
incorporated a hospitalization cost associated with such an acute event, as well as annual costs
afterwards. The cost of SAEs was from a publication [20] but was only applied in the year
when an SAE occurred. A detailed description of costs can be found in the “Cost” section of S1
Text and in Table D in S1 Text.
We calculated utilities by age and sex for patients with hypertension based on a Chinese
population; however, as in our previous work [13], for a CVD event we adopted utility values
used in other cost-effectiveness studies. Since utilities associated with SAEs were not available,
we assumed a utility of 0.5 for 1 week before returning to the previous health state. This
approach has been adopted and justified in previous studies [21,22].
Model validation. We validated the model through 2 strategies: First, we compared the
projected life expectancy in our model with that from China life tables in 2017 [6]. Second, we
also computed the predicted 5-year coronary heart disease, stroke, HF, and mortality rates
among people with standard treatment from our base-case model and compared these with
published data.
Base-case and sensitivity analyses. Since there is no commonly accepted cost-effective-
ness threshold for China, we adopted the one calculated using the method previously recom-
mended by the World Health Organization [23]. Here, an incremental cost-effectiveness ratio
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(ICER) below Int$16,782 (China’s gross domestic product per capita in 2017) implies that the
intensive SBP treatment is cost-effective compared to standard treatment.
In order to examine the effect of the uncertainty of each model parameter on the result
from our base-case analysis, we varied each input value in our model over a plausible range in
a series of 1-way sensitivity analyses. In addition to the above deterministic sensitivity analyses,
we conducted probabilistic sensitivity analyses by running our model 1,000 times, with each
run sampling from prespecified distributions of each parameter. The plausible ranges and dis-
tributions for each of the model parameters are detailed in Table C and Table D in S1 Text.
Results
Number and characteristics of Chinese adults meeting SPRINT eligibility
criteria
Overall, 22.2% (95% CI 20.5% to 23.0%) of Chinese adults, representing 116.2 (95% CI 107.5
to 124.8) million people, met the SPRINT criteria (Figs 1 and 2). Among Chinese adults with
hypertension, 41.4% (95% CI 37.8% to 45.1%), or 93.3 million, were eligible for SPRINT. This
is compared to 37.9% (95% CI 34.4%, 41.5%), or 22.8 million, among Chinese adults without
hypertension (i.e., with SBP 130–139 mm Hg). Additionally, among those with treated hyper-
tension, 37.2% (95% CI 33.6% to 40.8%), or 39.0 million, may benefit from further SBP reduc-
tion (Fig 2). The number of adults meeting each sequential SPRINT eligibility criterion are
detailed in Table B in S1 Text.
Compared with the overall study population, those eligible for SPRINT were more likely to
be older, to be male, to smoke, and to have a SBP� 140 mm Hg (Table A in S1 Text). It is
noted that, of those SPRINT-eligible adults, 77.1 million (66.4%) were not being treated for
hypertension, and 26.6 million (22.9%) had a SBP of 130 to 139 mm Hg, yet were not taking
antihypertensive medications.
Model validation
The predictions of our microsimulation model for life expectancy and rates of MI, stroke,
CVD mortality, and all-cause mortality over the 5-year period were similar to those published
in other real-world Chinese studies (Table E in S1 Text).
Base-case analysis
Compared to standard treatment, intensive SBP treatment was predicted to reduce the inci-
dence rate of HF within 5 years by 0.72% (95% CI 0.36%, 1.08%) and CVD mortality by 1.75%
(95% CI 1.24%, 2.26%), though it was not predicted to significantly reduce the incidence rate
for MI (0.06%; 95% CI −0.24, 0.36%) or stroke (0.31%; 95% CI 0.09%, 0.71%). Correspond-
ingly, we estimate the 5-year event reduction would be 0.84 (95% CI 0.42, 1.25) million for HF,
2.03 (95% CI 1.44, 2.63) million for CVD mortality, 0.069 (95% CI −0.28, 0.42) million for MI,
and 0.36 (95% CI −0.10, 0.82) million for stroke. Taken together, 3.84 (95% CI 1.53, 6.34) mil-
lion life-years could be saved within 5 years via intensive SBP treatment compared to standard
treatment, and 11.06 (95% CI 9.7, 14.73) million life-years over a lifetime (Fig 3; Table F in
S1 Text).
The potential changes in QALYs and total cost (consisting of antihypertension treatment
costs, cost of SAEs, and cost of complications) over a lifetime are summarized in Table 1 and
Table G in S1 Text. Intensive SBP treatment led to a gain of 0.38 QALYs (95% CI 0.13, 0.71),
while increasing costs from $7,861 to $11,395 (an increment of $3,777 [95% CI −$208,
$8,286]). This means that compared to standard treatment, intensive SBP treatment costs
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Fig 1. Flow chart showing the eligibility criteria for SPRINT applied to the present study. Total number of baseline
participants of the China Health and Retirement Longitudinal Study was 17,708. After excluding missing blood pressure
values, there were 13,483 eligible participants included in the present analysis. CVD, cardiovascular disease; SPRINT,
Systolic Blood Pressure Intervention Trial.
https://doi.org/10.1371/journal.pmed.1003515.g001
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$10,997 (−$752, $29,027) per additional QALY gained. The estimate of the cost-effectiveness
of intensive SBP treatment in most subgroups of interest was similar to the overall estimate,
although less favorable ICERs were estimated for men ($12,259 per QALY gained) and those
with SBP 130–139 mm Hg ($13,277 per QALY gained).
Fig 2. Number of Chinese adults (age� 45 years) meeting each sequential SPRINT eligibility criterion. The circles are proportional to the population sizes.
Hypertension defined as SBP� 140 mm Hg or diastolic blood pressure� 90 mm Hg or taking antihypertensive medication. CI, confidence interval; CVD,
cardiovascular disease; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.
https://doi.org/10.1371/journal.pmed.1003515.g002
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Uncertainty analysis
We assessed the uncertainty in the estimates by means of 1,000 probabilistic simulations.
Overall, there was an 82.8% probability that intensive treatment was cost-effective at a willing-
ness-to-pay threshold of $16,782 per QALY (1× GDP per capita in 2017) and a 98.1% probabil-
ity at a threshold of $33,564 per QALY (2× GDP per capita in 2017) (Table 1; S3 and S4 Figs).
The probability of being cost-effective varied across different subgroups at a threshold of 1×
GDP per capita; however, it became stable (around 98% probability of being cost-effective) if
the threshold increased to 2× GDP per capita.
Results in S2 Fig show that our cost-effectiveness outcome is relatively insensitive to a vari-
ety of alternate assumptions, with estimated ICERs all below 1× GDP per capita (with the
exception of cost for antihypertensive medication). There were 8 parameters that were espe-
cially influential to our ICER estimates: cost for antihypertensive medication, relative risk of
CVD death from treatment, relative risk of stroke from treatment, cost for SAE, cost for post-
Fig 3. Base-case 5-year and lifetime events reduced for different outcomes. “Events reduced” refers to events that would be reduced if the intensive treatment
were in place instead of standard treatment. It is calculated by multiplying the event difference from our simulation by the number of SPRINT-eligible adults.
CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003515.g003
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aTo convert cost input to Chinese currency, one would multiply the cost by the purchasing power parity (PPP) rate (in this case, 3.54). Total cost includes
antihypertension treatment costs, cost of complications, and serious adverse event costs.
bProbabilistic analyses based on running the model 1,000 times with the use of randomly selected values for input measurements from predefined distributions. The UIs
show the 2.5 to 97.5 percentiles for the incremental differences in costs and QALYs. The uncertainty of the ICER, which was calculated as the cost per QALY gained, is
shown by the probability that intensive control is cost-effective at the specified willingness-to-pay thresholds.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SBP, systolic blood pressure; UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1003515.t001
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stroke care, utility for SAE, relative risk of SAE from treatment, and relative risk of HF from
treatment.
Discussion
Using nationally representative data we found that the SPRINT intensive SBP treatment strat-
egy could increase the number receiving SBP treatment initiation or intensification to more
than 116 million adults in China, which is 22.2% of the population. Furthermore, through a
validated microsimulation model we projected that over 5 years more than 2.03 million CVD
deaths could be prevented, and 3.84 million life-years could be saved, if an intensive SBP treat-
ment target of<120 mm Hg for selected high-risk patients were adopted. In addition, our
study found that intensive SBP treatment would cost Int$10,997 per QALY gained and was
likely to be cost-effective (82.8% probability of being below 1× GDP per capita for China in
2017).
In 2 previous studies from the US and Canada, the investigators found that 7.6% of US
adults and 5.2% of Canadian adults meet the SPRINT eligibility criteria, yet our estimate for
China was much higher (22.2%). These results suggest that the uncontrolled hypertension rate
in China is higher than in the US and Canada. Furthermore, with such a large population, the
absolute number of people who would benefit is considerably larger in China (116 million ver-
sus 16.8 million for the US and 1.3 million for Canada) [24,25]. Remarkably, we estimated that
two-thirds (66.4%) of those meeting SPRINT eligibility criteria were not treated for hyperten-
sion, which was higher than the estimates for the US (50.6%) and Canada (40.4%). Addition-
ally, we found that 22.9% of them had SBP of 130 to 139 mm Hg, and would not previously
have been considered to have hypertension and therefore would not have been recommended
to take antihypertensive medication under hypertension guidelines in China [19]. Corre-
spondingly, this proportion was 19.6% in the US and 14.3% in Canada. Taken together, these
findings imply that a larger population would be affected in China if intensive SBP treatment
were fully implemented.
Although significant benefits from intensive SBP goals have been demonstrated in a recent
meta-analysis of 34 BP-lowering trials including SPRINT [9], there is still considerable debate
over the number of SAEs and the additional investments likely required, e.g., increased drug
and monitoring costs [24,26]. In addressing these issues, our modeling suggests that intensive
SBP treatment could reduce CVD mortality and produce gains in life-years, but with increased
risk of SAEs. These findings are consistent with a report in the US population, which projected
over 100,000 deaths prevented annually, but at the cost of a considerable increase in SAEs [26].
However, from a lifetime perspective, our study provides evidence to suggest that the increased
costs from BP intensification and management of SAEs are offset by health gains from pre-
vented CVD events and deaths. The ICER for intensive SBP treatment was less than 1× GDP
per capita for China in 2017, with a high probability of cost-effectiveness overall (i.e., 82.8%)
and in subgroups of interest (e.g., 72.9% for those with SBP between 130 and 139 mm Hg, and
91.2% for the female population). Our findings, together with those of 3 other studies with
similar conclusions from the US [22,27,28], suggest that intensive SBP treatment among high-
risk populations is worthy of significant capital investment, generating QALYs through reduc-
ing CVD mortality and long-term morbidity. This is also supported by our previous research,
in which we found that the adoption of SBP treatment among people with SBP between 130
and 139 mm Hg could be cost-effective.
The present study has some limitations. First, not all the information required to assess eli-
gibility for SPRINT was collected by the CHARLS survey. However, the effect of not having
taken into account these certain conditions, which are expected to have a very low rate, is
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thought to be minimal. Second, like all other computer simulation analyses, our approach
relied on data derived from multiple sources and study types, in particular, the findings from
SPRINT among the US population. Third, there is limited information on the incidence of
each of the SAEs reported in SPRINT (e.g., hypotension, syncope); therefore, we could not
detail the components of SAEs in our model. Also, the scarcity of data and the uncertainty of
the effect of intensive management on renal complications prevented us from including long-
term renal outcomes in the model. Fourth, BP measurements in SPRINT were likely done by
unattended automated BP devices, which are different from the one used in CHARLS, with
staff attendance during BP measurement. Studies have shown that unattended BP measure-
ment can result in BP values that are 10–15 mm Hg lower. This may have affected the propor-
tion of people meeting SPRINT criteria and our further modeling results. That said, evidence
has shown a similar BP level and CVD risk reduction in the intensive SBP treatment group in
SPRINT participants regardless of the measurement technique [29]. Fifth, our estimations of
the number and proportion of Chinese adults meeting SPRINT eligibility criteria are based on
survey data at 1 time point (i.e., 2011–2012), and these values may have changed with time,
particularly for those with versus without hypertension treatment. Finally, although BP treat-
ment intensification, like many other interventions, cannot not ultimately prevent the death
of people, it may alter their disease progress or pathway. Therefore, our estimates of the events
or deaths reduced may be confounded by the competing risk between CVD event and CVD
death or non-CVD death, particularly for the lifetime estimates.
The approach described in SPRINT has had a dramatic influence on clinical practice
[11,12]. The present study suggests that adoption of the SPRINT intensive SBP treatment strat-
egy would reclassify 116 million Chinese adults as requiring SBP-lowering therapy, and if
these individuals were treated, we could prevent over 2 million CVD deaths, and gain 3.84 mil-
lion life-years over 5 years. Furthermore, this strategy is likely to be cost-effective over a life-




S1 Fig. Schematic depiction of the model structure. HF, heart failure; MI, myocardial
infarction.
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S2 Fig. One-way sensitivity analysis of model variables. Red dashed line: 1 GDP per capita.
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S3 Fig. Results of the probabilistic analyses as shown in a cost-effectiveness scatter plot.
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S4 Fig. Cost-effectiveness acceptability curves.
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